First or Second Biologic in Inflammatory Bowel Disease: Combination Therapy or Monotherapy?
Roni Aoun1, Suha Jabak1, Fadi H Mourad1
1Division of Gastroenterology and Hepatology, American University of Beirut Medical Center, Beirut, Lebanon.
Journal of Clinical Gastroenterology
|July 23, 2021
Summary
For inflammatory bowel disease (IBD) patients, optimal biologic therapy (monotherapy or combination) is unclear for those on second or later treatments. This review examines current data for first and subsequent biologic use in IBD management.
Area of Science:
- Gastroenterology and Immunology
- Inflammatory Bowel Disease (IBD) Research
- Biologic Therapies in Medicine
Background:
- The range of treatments for inflammatory bowel disease (IBD) is growing.
- Current guidelines offer recommendations for biologic-naive patients regarding biologic monotherapy versus combination therapy.
- Clinical guidance for patients receiving their second or subsequent biologic therapy is limited due to insufficient data.
Purpose of the Study:
- To review existing data on biologic monotherapy versus combination therapy with immunomodulators.
- To provide insights for clinical practice concerning first-line and subsequent biologic treatments in IBD.
- To address the lack of guidance for patients on advanced biologic therapies.
Main Methods:
- Systematic review of available clinical data.
- Analysis of treatment strategies in inflammatory bowel disease.
- Comparison of biologic monotherapy and combination therapy outcomes.
Main Results:
- Data on biologic monotherapy versus combination therapy is available for first-line biologic treatment in IBD.
- Limited but emerging data exists for patients receiving second or subsequent biologic therapies.
- Treatment strategies may differ based on prior biologic exposure and drug class.
Conclusions:
- Further research is needed to establish optimal strategies for patients on second or later biologics in IBD.
- Understanding the efficacy of combination therapy in IBD requires more investigation for advanced treatment lines.
- Evidence-based recommendations for subsequent biologic use in IBD are crucial for improving patient outcomes.
More Related Videos
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
8.4K
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.9K
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
246
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
246
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
264
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
264
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
291
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
291
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
251
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
251
01:29Drugs for Treatment of Ulcerative Colitis in IBD
280
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
280
01:28Drug Products: Biologics, Biosimilars and Interchangeables
53
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
53